Evaluating Surrogate Marker Information using Censored Data by Parast, Layla et al.
ar
X
iv
:1
60
2.
05
89
4v
2 
 [s
tat
.M
E]
  1
0 A
ug
 20
16
Evaluating Surrogate Marker Information using Censored
Data
Layla Parast1, Tianxi Cai2, Lu Tian3
1RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, parast@rand.org
2Harvard University, Department of Biostatistics, Boston, MA 02115
3 Stanford University, Department of Health, Research and Policy, Stanford, CA 94305
1
Summary
Given the long follow-up periods that are often required for treatment or intervention studies,
the potential to use surrogate markers to decrease the required follow-up time is a very attractive
goal. However, previous studies have shown that using inadequate markers or making inappropri-
ate assumptions about the relationship between the primary outcome and surrogate marker can
lead to inaccurate conclusions regarding the treatment effect. Currently available methods for
identifying and validating surrogate markers tend to rely on restrictive model assumptions and/or
focus on uncensored outcomes. The ability to use such methods in practice when the primary
outcome of interest is a time-to-event outcome is difficult due to censoring and missing surrogate
information among those who experience the primary outcome before surrogate marker measure-
ment. In this paper, we propose a novel definition of the proportion of treatment effect explained
by surrogate information collected up to a specified time in the setting of a time-to-event primary
outcome. Our proposed approach accommodates a setting where individuals may experience the
primary outcome before the surrogate marker is measured. We propose a robust nonparametric
procedure to estimate the defined quantity using censored data and use a perturbation-resampling
procedure for variance estimation. Simulation studies demonstrate that the proposed procedures
perform well in finite samples. We illustrate the proposed procedures by investigating two poten-
tial surrogate markers for diabetes using data from the Diabetes Prevention Program.
Keywords: nonparametric methods, robust procedures, smoothing, survival analysis
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1 Introduction
A surrogate marker is often defined as a physical measurement such as a biomarker, clinical mea-
surement, or psychological test that can be “used in therapeutic trials as a substitute for a clinically
meaningful endpoint that is a direct measure of how a patient feels, functions, or survives and is
expected to predict the effect of the therapy.”(Temple, 1999) The quest to identify, validate, and use
surrogate markers in practice is driven by the potential for such markers to reduce the length of stud-
ies that currently require very long follow-up periods. For example, studies with outcomes such as
cancer diagnosis, diabetes diagnosis, or heart attack often require many years of follow-up to precisely
estimate an intervention effect. Research involving the identification and validation of surrogate mark-
ers has been active with much novel methodological development and heated debate. In a landmark
paper, Prentice (1989) introduced a criterion for a valid surrogate marker which required that a test
for treatment effect on the surrogate marker is also a valid test for treatment effect on the primary
outcome of interest. Since then, numerous approaches have been developed to identify and validate
surrogate markers and to quantify the “surrogacy” of such markers. For example, motivated by the
Prentice criterion, Freedman et al. (1992) proposed to estimate the proportion of treatment effect that
is explained by a surrogate marker by examining the change in the regression coefficient for treatment
when the surrogate marker is added to a specified regression model. Wang & Taylor (2002) proposed a
more flexible model-based approach to estimate the proportion of treatment effect explained by defin-
ing a quantity that attempts to capture what the the effect of the treatment in the treatment group
would be if the values of the surrogate were distributed as those in the control group. Building from
the definition of Wang & Taylor (2002), Parast et al. (2016) proposed a robust estimation procedure
to estimate this quantity without the requirement of correct model specification. However, none of
these approaches are able to adequately accommodate settings with time-to-event outcomes.
While the proportion of treatment effect explained by a surrogate marker is intuitively appealing, a
number of other quantities to assess surrogate markers have been proposed. For example, relative effect
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and adjusted association (Buyse & Molenberghs, 1998), indirect and direct effects (Robins & Greenland, 1992),
dissociative effects, associative effects, average causal necessity, average causal sufficiency, and the
causal effect predictiveness surface in a principal stratification framework (Frangakis & Rubin, 2002;
Huang & Gilbert, 2011; Gilbert & Hudgens, 2008; Conlon et al., 2014b) are some of the alternative
quantities that are available. Again however, the majority of these currently available methods were
developed for settings where the primary outcome is fully observable and cannot be easily extended
to settings with time-to-event outcomes.
For a survival outcome, T , existing methods largely require restrictive model assumptions that may
not hold in practice. Lin et al. (1997) extended the approach proposed by Freedman et al. (1992) to
the survival setting but showed that it is actually impossible for both of the two specified survival
models to hold simultaneously. The survival setting is often further complicated by the fact that the
surrogate marker, S, itself may be missing. That is, the individual may be censored or may expe-
rience the primary outcome before S is measured, in which case S will not be observable and thus,
commonly used metrics for surrogacy would not be well-defined. When both T and S are subject to
censoring, Ghosh (2008) proposed estimation and inference procedures for the proportion of treatment
effect explained by a surrogate using an accelerated failure time (AFT) model and demonstrated de-
sirable finite sample performance when the AFT model holds. Ghosh (2009) proposed estimates of
quantities to assess the validity of a surrogate marker in a semi-competing risks framework such that
estimates are derived based on specified copula model and AFT models. However, their simulations
demonstrate that when the assumed copula model is misspecified, the proposed procedure leads to
biased estimates that persist with large sample sizes. In the principal stratification framework, mul-
tiple quantities for evaluating potential surrogate markers in a time-to-event outcome setting have
been proposed by Conlon et al. (2014a), using a Gaussian copula model with a Bayesian estimation
approach. Gabriel & Gilbert (2014) and Gabriel et al. (2015) rely on flexible yet still model-based
procedures using Weibull time-to-event models for the primary outcome. These methods would yield
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estimates that are difficult to interpret under model mis-specifications. It is thus of great interest to
investigate methods that do not rely on correct model specification and are applicable to the survival
setting where both T and S are subject to censoring.
In this paper, we generalize the work of Parast et al. (2016) and propose a novel model-free frame-
work for quantifying the proportion of treatment effect explained by surrogate information collected
up to a specified time, t0, in the survival setting. In addition, we propose a robust nonparametric
procedure to estimate the defined quantity using censored data and a perturbation-resampling pro-
cedure for inference. To increase efficiency, we also propose parallel augmented estimates that take
advantage of baseline covariate information. Our proposed definition and estimation procedure is the
only available method to accommodate survival settings where individuals may experience the primary
outcome of interest or be censored before the surrogate marker is measured, a situation that is quite
common in practice. We perform a simulation study to examine the finite sample performance of our
proposed procedures and illustrate the proposed procedures by investigating two potential surrogate
markers for diabetes using data from the Diabetes Prevention Program.
2 Setup and Definitions in a Causal Inference Framework
Let G be the binary treatment indicator with G = A for treatment A and G = B for treatment
B and we assume throughout that subjects are randomly assigned to a treatment group at baseline.
Let T denote the survival time of interest and S denote the surrogate marker value measured at
time t0. Without loss of generality, we assume that S only takes positive values (if not, we may
simply exponentiate S). To study this problem under the causal inference framework, we use potential
outcomes notation such that T (g) and S(g) denote the survival time and the surrogate marker value
under treatment G = g. That is, T (A), T (B), S(A) and S(B) denote the survival time under treatment
A, survival time under treatment B, surrogate marker value under treatment A and surrogate marker
value under treatment B, respectively. We assume that S(B) and S(A) have the same support. In
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practice, we can only potentially observe (T, S) = (T (A), S(A)) or (T (B), S(B)) for each individual
depending on whether G = A or B. Throughout, we define the treatment effect, ∆(t), as the difference
in survival rates by time t under treatment A versus under treatment B,
∆(t) = E{I(T (A) > t)} −E{I(T (B) > t)} = P (T (A) > t)− P (T (B) > t)
where t > t0. We consider a setting where individuals may be censored or experience the primary
outcome before t0 and thus, S may not be observable for these patients. For simplicity, we assume
that the surrogate marker cannot be measured after the primary outcome occurs, which is a reasonable
assumption if, for example, the primary outcome is death, but discuss this assumption further in the
Remarks.
Our analytic objective is to study the extent to which the surrogate information available at time t0
captures the true treatment effect ∆(t). It is important to consider whether information concerning the
primary outcome observed before t0 should be considered as part of the surrogate information available
at t0. We argue that this information should indeed be considered as part of the surrogate information.
That is, in this paper, we define surrogate information at t0 as the combination of primary outcome
information before t0 and surrogate marker measurements collected at t0 for those still being observed.
We take this approach because even in the highly optimistic situation where one were to identify
S, measured at t0, as a valid surrogate marker that can be used to estimate and test for a treatment
effect, it is unlikely that one would completely disregard primary outcome information that is observed
up to t0. It is more sensible to envision that one uses both primary outcome information before t0
and surrogate marker measurements at t0 to estimate the treatment effect, thus this combination of
information is our definition of surrogate information at t0 throughout this paper. Specifically, we
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consider the surrogate information available at t0 as
Q
(g)
t0
= {T (g) ∧ t0, S(g)I(T (g) > t0)}, g = A,B.
Further motivating this definition is the fact that it is difficult to consider a reasonable alternative to
this approach. For example, one potential alternative would be to restrict estimation to only those who
are still under observation at t0 (i.e. removing individuals who experience the primary outcome before
t0) (Lin et al., 1997; Gabriel et al., 2015). However, it does not seem desirable to assess surrogacy on
only a selected subset of survivors systematically different from the original population, nor does it
seem reasonable to disregard observed information on T before t0 when the goal is to quantify the
treatment effect on T .
We aim to define the proportion of treatment effect explained by Qt0 by contrasts between the actual
treatment effect and the residual treatment effect that would be observed if the surrogate information
available at t0 under treatment A was equal to the surrogate information available at t0 under treatment
B. That is, we define the residual treatment effect by noting that
E
{
I(T (A) > t)− I(T (B) > t) | Q(A)t0 = Q(B)t0 = qt0
}
= I(st0 > 0)∆
+
S (t, t0, st0)
where qt0 = {ut0 , st0} = {u ∧ t0, sI(u > t0)}, and
∆+S (t, t0, s) = E{I(T (A) > t)− I(T (B) > t) | S(A) = S(B) = s, T (A) > t0, T (B) > t0}.
Thus, ∆S(t, t0, st0)= I(st0 > 0)∆
+
S (t, t0, st0) defines the hypothetical difference in survival at t if the
surrogate information available at time t0, Qt0 , in both treatment groups was identical to qt0 . Inter-
estingly, ∆S(t, t0, st0) only depends on qt0 through st0 . An equivalent interpretation of ∆S(t, t0, st0)
would be the hypothetical difference in survival at t if both the survival distribution up to t0 and the
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distribution of the surrogate marker at t0 among those who survived to t0 were the same in the two
treatment groups. This quantity summarizes the residual treatment effect that cannot be explained by
the surrogate information available at t0 and would be expected to equal zero for a perfect surrogate
marker.
However, ∆+S (t, t0, s) is generally not identifiable since S
(A) and S(B) cannot both be observed simul-
taneously. To overcome this difficulty, we further assume that
T (A) ⊥ S(B)(T (B) > t0) | {S(A), T (A) > t0} (2·1)
T (B) ⊥ S(A)(T (A) > t0) | {S(B), T (B) > t0} (2·2)
Under assumptions (2·1) and (2·2),
∆+S (t, t0, st0) = ψA(t | st0 , t0)− ψB(t | st0 , t0)
where for g = A,B,
ψg(t | s, t0) = P (T (g) > t | S(g) = s, T (g) > t0).
To consider the residual treatment effect in a population, we may consider st0 as a realization from
a random distribution St0 and define the residual treatment effect as
∆S(t, t0) = E{∆S(t, t0,St0)} = P (St0 > 0)E
{
∆+S (t, t0,St0)
}
.
The choice of the distribution of St0 depends on the specific context. For example, if treatment B
is a placebo, then we may be interested in examining the residual treatment effect quantity when
treatment A has no effect on the surrogate marker information at t0, i.e., when the distribution of the
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surrogate information at t0 under treatment A is the same as that under treatment B. In this case,
St0 ∼ I(T (B) > t0)S(B)
and
∆S(t, t0) =P (T
(B) > t0)E
{
∆+S (t, t0, S
(B)) | TB > t0
}
(2·3)
=P (T (B) > t0)
[
E
{
ψA(t | S(B), t0) | TB > t0
}−E {ψB(t | S(B), t0) | TB > t0}]
=P (T (B) > t0)
{∫
ψA(t | s, t0)dFB(s | t0)− P (T (B) > t | T (B) > t0)
}
, (2·4)
where Fg(· | t0) is the cumulative distribution function of S(g) conditional on T (g) > t0. Here treatment
group B, the placebo group, serves as the reference distribution for the definition of ∆S(t, t0). Alterna-
tively, when neither treatment A nor treatment B is a natural reference group, one may be interested
in examining the residual treatment effect when the distribution of the surrogate information at t0 in
both groups are identical to that of a mixture population from the two groups. For example, in this
case we may let
St0 ∼
1
2
I(T (A) > t0)S
(A) +
1
2
I(T (B) > t0)S
(B)
and
∆S(t, t0) =
∫
∆+S (t, t0, s)d
{
1
2
P (T (A) > t0)FA(s | t0) + 1
2
P (T (B) > t0)FB(s | t0)
}
. (2·5)
For a given choice of ∆S(t, t0), the proportion of treatment effect explained by the surrogate marker
can be expressed using a contrast between ∆(t) and ∆S(t, t0):
RS(t, t0) = {∆(t)−∆S(t, t0)}/∆(t) = 1−∆S(t, t0)/∆(t). (2·6)
In this paper, we focus on nonparametrically estimating this proportion using censored data. Infor-
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mally, we use RS(t, t0) to measure the extent to which the surrogate marker captures information
about the treatment effect on survival by comparing the total treatment effect with the hypothetical
treatment effect when there is no difference in surrogate information up at t0. The approach to defining
the proportion of treatment effect explained based on contrasts between the actual treatment effect
and the residual treatment effect was proposed in a non-survival setting in Wang & Taylor (2002)
and further developed in Parast et al. (2016). Our definition generalizes their proposed approach to
a setting where the outcome may be a time-to-event outcome, individuals may be censored, and in-
dividuals may not have surrogate marker information available because they either experienced the
primary outcome or were censored before the time of surrogate marker measurement.
Remark. This definition of the proportion of the treatment effect explained by the surrogate marker
does not guarrantee that the resulting RS(t, t0) is always between 0 and 1. However, one set of sufficient
conditions similar to those given in Wang & Taylor (2002) is
(C1) ψA(t|s, t0) is a monotone increasing function of s;
(C2) P (S(A) > s, T (A) > t0) ≥ P (S(B) > s, T (B) > t0) for all s;
(C3) ψA(t|s, t0) ≥ ψB(t|s, t0) for all s;
where the first condition implies that the surrogate marker at time t0 is “positively” related to the
survival time; the second condition implies that there is a positive treatment effect on the surrogate
marker and the third condition suggests that there is a non-negative residual treatment effect beyond
that on the surrogate marker. For (C1), 1/S can be used to replace S if the surrogate markers is
“negatively” associated with the survival time. In Appendix A in the Supplementary Materials, we
show that under conditions (C1)-(C3), 0 ≤ ∆S(t, t0) ≤ ∆(t) and 0 ≤ RS(t, t0) ≤ 1.
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3 Nonparametric Estimation of the proportion of treatment effect explained
The quantity RS(t, t0) depends on the selection of the reference distribution St0 . When the treatment
group B represents standard care or a placebo, the ∆S(t, t0) definition (2·4) seems intuitive. However,
when neither group is a natural reference group, a new distribution may be considered such as the one
used for the ∆S(t, t0) definition (2·5). For simplicity, we focus on the development of an estimation and
inference procedure for the definition based on (2·4); however, parallel procedures would be applicable
for other choices of a reference distribution.
Due to censoring, the observed data consist of {(Xgi, δgi, Sgi), i = 1, ..., ng; g = A,B}, where Xgi =
min(Tgi, Cgi), δgi = I(Tgi < Cgi), Cgi denotes the censoring time, and Sgi denotes the surrogate marker
information measured at time t0, for g = A,B, for individual i. We assume that (Tgi, Sgi) ⊥ Cgi.
Throughout, we estimate the treatment effect ∆(t) = P (T (A) > t)− P (T (B) > t) as
∆̂(t) = n−1A
nA∑
i=1
I(XAi > t)
ŴCA (t)
− n−1B
nB∑
i=1
I(XBi > t)
ŴCB (t)
where ŴCg (·) is the Kaplan-Meier estimator of survival for censoring for g = A,B. Note that this
estimator is asymptotically equivalent to the difference of two Kaplan-Meier estimators for the survival
time (see Appendix B in the Supplementary Materials).
3·1 Nonparametric estimator of the proportion of treatment effect explained
To estimate ∆S(t, t0) as defined in (2·4), we need to estimate
ψA(t | s, t0) = P (T (A) > t | T (A) > t0, S(A) = s) and FB(s | t0) = P (S(B) ≤ s | T (B) > t0).
Note that ψA(t | s, t0) = P (TAi > t | XAi > t0, SAi = s) given our earlier assumption that (Tgi, Sgi) ⊥
Cgi. We propose to use a nonparametric kernel Nelson-Aalen estimator to estimate ψA(t | s, t0) as
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ψ̂A(t | s, t0) = exp{−Λ̂A(t | s, t0)}, where
Λ̂A(t | s, t0) =
∫ t
t0
∑nA
i=1 I(XAi > t0)Kh{γ(SAi)− γ(s)}dNAi(z)∑nA
i=1 I(XAi > t0)Kh{γ(SAi)− γ(s)}YAi(z)
,
is a consistent estimate of ΛA(t | s, t0) = − log[ψA(t | s, t0)], YAi(t) = I(XAi ≥ t), NAi(t) = I(XAi ≤
t)δi, K(·) is a smooth symmetric density function, Kh(x) = K(x/h)/h, γ(·) is a given monotone
transformation function, and h is a specified bandwidth. To obtain an appropriate h, we require the
standard undersmoothing assumption of h = O(n−uA ) with u ∈ (1/4, 1/2) in order to eliminate the
impact of the bias of the conditional survival function on the resulting estimator. We first use the
bandwidth selection procedure given by Scott (1992) to obtain hopt; and then we let h = hoptn
−c0
A for
some c0 ∈ (1/20, 3/10) to ensure the desired rate for h. In all numerical examples, we chose c0 = 0.11.
Since FB(s | t0) = P (SBi ≤ s | XBi > t0), we empirically estimate FB(s | t0) using all subjects with
XBi > t0 as
F̂B(s | t0) =
∑nB
i=1 I(SBi ≤ s,XBi > t0)∑nB
i=1 I(XBi > t0)
.
Subsequently, we may construct an estimator for ∆S(t, t0) as
∆̂S(t, t0) = n
−1
B
nB∑
i=1
[
ψ̂A(t | SBi, t0)I(XBi > t0)
ŴCB (t0)
− I(XBi > t)
ŴCB (t)
]
and R̂S(t, t0) = 1−∆̂S(t, t0)/∆̂(t). In Appendix B in the Supplementary Materials, we show that under
mild regularity conditions ∆̂S(t, t0) is a consistent estimator of ∆S(t, t0) and that as nA, nB →∞,
√
n
 ∆̂S(t, t0)−∆S(t, t0)
∆̂(t)−∆(t)
→ N(0,Σ∆),
where n = nA + nB. It then follow that R̂S(t, t0) is a consistent estimator of RS(t, t0) and, by the
delta method,
√
n{R̂S(t, t0)− RS(t, t0)} converges weakly to a mean zero normal distribution with a
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variance of σ2R.
3·2 Augmentation for improved efficiency using baseline covariates
Recent work has shown that augmentation can lead to improvements in efficiency by taking advan-
tage of the association between baseline information, Z, and the primary outcome (Tian et al., 2012;
Garcia et al., 2011; Zhang et al., 2008). To investigate whether it is possible to gain efficiency through
augmentation in this setting we propose the augmented estimates:
 ∆̂(t)AUG
∆̂S(t, t0)
AUG
 =
 ∆̂(t)
∆̂S(t, t0)
 +A{n−1A nA∑
i=1
h(ZAi)− n−1B
nB∑
i=1
h(ZBi)
}
(3·1)
and
R̂(t, t0)
AUG = 1− ∆̂S(t, t0)
AUG
∆̂(t)AUG
where Zgi, i = 1, 2, · · · , ng are i.i.d. random vectors of baseline covariates from treatment group g
and h(·) is a basis transformation given a priori. Due to treatment randomization, n−1A
∑nA
i=1 h(ZAi)−
n−1B
∑nB
i=1 h(ZBi) converges to zero in probability as the sample size goes to infinity and thus the
augmented estimator converges to the same limit as the original counterparts. We propose to select
A such that the variance of (∆̂(t)AUG, ∆̂S(t, t0)AUG)′ is minimized. That is, A = (Ξ12)(Ξ22)−1 where
Ξ12 = cov

 ∆̂(t)
∆̂S(t, t0)
 , n−1A nA∑
i=1
h(ZAi)− n−1B
nB∑
i=1
h(ZBi)
 ,
Ξ22 = var
{
n−1A
nA∑
i=1
h(ZAi)− n−1B
nB∑
i=1
h(ZBi)
}
and thus we can obtain ∆̂(t)AUG by replacing A with a consistent estimator, Â. We approximate A
using a perturbation resampling approach described in Section 4.
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3·3 Incremental value of Surrogate Marker S Measurements at t0
Since our definition of ∆S(t, t0) considers the surrogate information as a combination of both S infor-
mation and T information up to t0, a logical inquiry would be how to assess the incremental value
of the S information in terms of the proportion of treatment effect explained, when added to T in-
formation up to t0. If the quantity RS(t, t0) reveals that a large proportion of the treatment effect
is explained by information at t0, it would be important to know how much of that quantity is at-
tributable to S information. If most of the surrogacy is due to T information up to t0, then it may
not be necessary to measure and incorporate S information. Similar to our definition of ∆S(t, t0) in
Section 2, we define the proportion of treatment effect explained by T information up to t0 only as
RT (t, t0) = 1 − ∆T (t, t0)/∆(t) where ∆T (t, t0) can be obtained by replacing S(A) = S(B) = 1, which
leads to
∆T (t, t0) =
1∑
dt0=0
E{I(T (A) > t)− I(T (B) > t) | I(T (A) > t0) = I(T (B) > t0) = dt0}F(dt0)
= F(1){P (T (A) > t | T (A) > t0)− P (T (B) > t | T (B) > t0)}
where F(d) = P (I = d) is the probability mass function for a binary random variable I.
As with ∆S(t, t0), the choice of F depends on the specific context. We will continue to assume,
without loss of generality, that treatment B is a placebo group and thus it is reasonable to consider
F(1) = P (T (B) > t0) as the reference distribution. It follows that
∆T (t, t0) = P (T
(B) > t0)P (T
(A) > t | T (A) > t0)− P (T (B) > t).
Although one would generally expect that the proportion of treatment effect explained by both S
and T information up to t0 to be at least as big as the proportion of treatment effect explained by T
information up to t0 alone (i.e. ∆(t) − ∆T (t, t0) ≤ ∆(t) − ∆S(t, t0) implying ∆T (t, t0) ≥ ∆S(t, t0)),
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this is only guaranteed to hold under certain conditions. Specifically, we note that
∆T (t, t0)−∆S(t, t0) = P (T (B) > t0)
∫
ψA(t | s, t0)d {FA(s | t0)− FB(s | t0)}
and therefore ∆T (t, t0)−∆S(t, t0) ≥ 0 if and only if
∫
ψA(t | s, t0)d {FA(s | t0)− FB(s | t0)} ≥ 0.
Sufficient conditions for the inequality above are (C1) and
P (S(A) > s|T (A) > t0) > P (S(B) > s|T (B) > t0) for all s.
These conditions are also required to ensure that we are not in a situation known as the surrogate
paradox VanderWeele (2013). When these conditions hold, it would be of interest to quantify the
surrogacy incremental value of S information as
IVS(t, t0) =
∆T (t, t0)−∆S(t, t0)
∆(t)
. (3·2)
To estimate RT (t0), we may employ the IPW estimator R̂T (t, t0) = 1 − ∆̂T (t, t0)/∆̂(t) where
∆̂T (t, t0) = φ̂B(t0)φ̂A(t)/φ̂A(t0) − φ̂B(t) and φ̂g(u) = n−1g
∑ng
i=1
I(Xgi>u)
ŴCg (u)
for g = A,B. Subsequently,
we may construct a plug-in estimator for IVS(t, t0) by replacing ∆(t),∆S(t, t0), and ∆T (t, t0) with
∆̂(t), ∆̂S(t, t0), and ∆̂T (t, t0), respectively.
4 Inference and Variance Estimation using Perturbation-Resampling
We propose to estimate the variability of our proposed estimators and construct confidence intervals
using a perturbation-resampling method to approximate the distribution of the estimators. Specifi-
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cally, let
{
V(b) = (V
(b)
A1 , ...V
(b)
AnA
, V
(b)
B1 , ...V
(b)
BnB
)T, b = 1, ...., D
}
be n×D independent copies of a positive
random variables V from a known distribution with unit mean and unit variance, such as the standard
exponential distribution. Let
∆̂(b)(t) =
∑nA
i=1 V
(b)
Ai I(XAi > t)∑nA
i=1 V
(b)
Ai Ŵ
C(b)
A (t)
−
∑nB
i=1 V
(b)
Bi I(XBi > t)∑nB
i=1 V
(b)
Bi Ŵ
C(b)
B (t)
,
Λ̂
(b)
A (t | s, t0) =
∫ t
t0
∑nA
i=1 V
(b)
Ai I(XAi > t0)Kh{γ(SAi)− γ(s)}dNi(z)∑nA
i=1 V
(b)
Ai I(XAi > t0)Kh{γ(SAi)− γ(s)}Yi(z)
,
∆̂
(b)
S (t, t0) =
∑nB
i=1 V
(b)
Bi ψ̂
(b)
A (t | SBi, t0)I(XBi > t0)∑nB
i=1 V
(b)
Bi Ŵ
C(b)
B (t0)
−
∑nB
i=1 V
(b)
Bi I(XBi > t)∑nB
i=1 V
(b)
Bi Ŵ
C(b)
B (t)
,
and
R̂
(b)
S (t, t0) = 1− ∆̂(b)S (t, t0)/∆̂(b)(t)
where ψ̂
(b)
A (t | s, t0) = exp{−Λ̂(b)A (t | s, t0)} and ŴC(b)g (·) is the Kaplan-Meier estimator of survival for
censoring with weights V
(b)
gi for g = A,B. Then one can estimate the distribution of
 ∆̂S(t, t0)−∆S(t, t0)
∆̂(t)−∆(t)
 (4·1)
by the empirical distribution of
 ∆̂(b)S (t, t0)− ∆̂S(t, t0)
∆̂(b)(t)− ∆̂(t)
 , b = 1, ..., D. (4·2)
That is, one can approximate the variance of (4·1) with the empirical variance of (4·2), denoted as
Σ̂. To construct a 100(1−α)% confidence interval for RS(t, t0), one can calculate the 100(α/2)th and
100(1−α/2)th empirical percentile of R̂(b)S (t, t0) or estimate the variance of R̂S(t, t0)−RS(t, t0) by the
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empirical variance of R̂
(b)
S (t, t0)−R̂S(t, t0) and construct the corresponding Wald-type confidence inter-
val. An alternative is to employ Fieller’s method for making inference on the ratio of two parameters
(Fieller, 1954; Fieller, 1940) and obtain the 100(1− α)% confidence interval for RS(t, t0) as
{
r :
{∆̂S(t, t0)− (1− r)∆̂(t, t0)}2
σˆ11 − 2(1− r)σˆ12 + (1− r)2σˆ22 ≤ cα
}
,
where Σ̂ = (σˆij)1≤i,j≤2 and cα is the 100× (1− α)th percentile of
{
[∆̂
(b)
S (t, t0)− {1− R̂S(t, t0)}∆̂(b)(t, t0)]2
σˆ11 − 2{1− R̂S(t, t0)}σˆ12 + {1− R̂S(t, t0)}2σˆ22
, b = 1, · · · , D
}
.
The theoretical justification for the perturbation-resampling procedure is provided in Appendix C in
the Supplementary Materials.
The perturbed samples can also be used to construct the augmented estimators ∆̂(t)AUG and
∆̂S(t, t0)
AUG, defined in (3·1), by replacing A with Â = (Ξ̂12)(Ξ̂22)−1, where Ξ̂12 is the empirical
covariance of

 ∆̂(b)(t)
∆̂
(b)
S (t, t0)
 , n−1A nA∑
i=1
V
(b)
Ai h(ZAi)− n−1B
nB∑
i=1
V
(b)
Bi h(ZBi)
 , b = 1, ..., D
and Ξ̂22 is the empirical variance of
{
n−1A
nA∑
i=1
V
(b)
Ai h(ZAi)− n−1B
nB∑
i=1
V
(b)
Bi h(ZBi)
}
, b = 1, ..., D.
The estimator R̂(t, t0)
AUG can be constructed accordingly.
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5 Numerical Studies
5·1 Simulation Studies
We conducted simulation studies under two main settings to assess the performance and validity
of our proposed estimators and inference procedures. In both settings, data were generated such
that individuals may experience the primary outcome or be censored before t0 and thus, S is only
measured on individuals still under observation at t0. Within each setting we examined results where
nA = nB = 1000 and nA = nB = 400. Throughout, we use a normal density kernel, t = 1, t0 = 0.5,
and the results summarize 1000 replications. For all estimates, we estimate variance using our proposed
perturbation approach and construct confidence intervals using the normal approximation, quantiles
of the perturbed values and Fieller’s method (for RS(t, t0) only).
In the first simulation setting, Setting (i), data were generated as:
S(A) ∼ Gamma(shape = 2, scale = 2)
S(B) ∼ Gamma(shape = 9, scale = 0.5)
T (A) | S(A), Z(A) = −log(1− Z(A))/(0.2× S(A))
T (B) | S(B), Z(B) = −log(1− Z(B))/(0.2 + 0.22× S(B))
and Z(A) and Z(B) were generated from a N(0, 1) distribution and censoring in both groups was
simulated as C ∼ Exp(0.5), where S(g) is only observable if T (g) > t0 and C > t0. In this setting,
∆(t) = 0.19, ∆S(t, t0) = 0.05, RS(t, t0) = 0.75, P (T
(A) > t) = 0.51, P (T (B) > t) = 0.32, P (T (A) >
t0) = 0.69, P (T
(B) > t0) = 0.56, E(S
(A)|T (A) > t0) = 3.35, E(S(B)|T (B) > t0) = 4.27, and 29% and
25% of individuals in treatment group A and treatment group B are censored before t, respectively.
The top portion of Table 1 shows the results from this setting when nA = nB = 1000. These results
show that in finite samples the proposed estimates have very small bias and adequate coverage, the
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standard error estimates obtained from the perturbation-resampling procedure are close to the average
standard error estimates, and augmentation provides some efficiency gain.
In the second simulation setting (ii), data were generated as:
S(A) ∼ Gamma(shape = 2, scale = 2)
S(B) ∼ Gamma(shape = 9, scale = 0.5)
T (A) | S(A), Z(A) = exp{0.5 ∗ S(A) + 1.5Z(A) + ǫ1}, ǫ1 ∼ N(0.5, 1)
T (B) | S(B), Z(B) = exp{0.1 ∗ S(B) + 1.5Z(B) + ǫ2}, ǫ1 ∼ N(0, 1)
and Z(A) and Z(B) were generated from a N(0, 1) distribution and censoring in both groups was
simulated as C = B ∗ e1 + (1 − B) ∗ e2, where B ∼ Bernoulli(0.5), e1 ∼ Exp(0.5), e2 ∼ Exp(0.3). In
this setting, ∆(t) = 0.27, ∆S(t, t0) = 0.11, RS(t, t0) = 0.60, P (T
(A) > t) = 0.87, P (T (B) > t) = 0.61,
P (T (A) > t0) = 0.93, P (T
(B) > t0) = 0.75, E(S
(A)|T (A) > t0) = 4.16, E(S(B)|T (B) > t0) = 4.56,
30% and 25% of individuals in treatment group A and treatment group B are censored before t,
respectively. The bottom portion of Table 1 shows the results from this setting when nA = nB = 1000.
Similar to setting (i), these results show that our proposed estimate performs well in finite samples;
specifically, the bias is very small, the coverage is adequate, the standard error estimates obtained
from the perturbation-resampling procedure are close to the average standard error estimates, and
augmentation provides some efficiency gain. For comparison, the estimate of Lin et al. (1997) in this
setting was -0.13 using Cox models and -0.40 using AFT models. In addition, we simulated data in this
same setting with the exception that censoring in both groups was simulated as C = exp{N(4, 1)};
with this change, the estimate of Lin et al. (1997) when nA = nB = 1000 was -0.06 using Cox models
and -0.76 using AFT models while the estimates from our proposed procedure look almost identical
to those shown in Table 1. The fact that this model-based approach a) provides a negative estimate
of the proportion of treatment effect explained by the surrogate and b) provides two rather different
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estimates when only the censoring distribution is changed demonstrates the advantage of utilizing a
method that does not require strict modeling assumptions in settings where they may not hold.
Table 2 shows results for both settings when nA = nB = 400. With a smaller sample size, we
recommend using the median absolute variance when calculating the empirical variance of the per-
turbed quantities (see Section 4) to guard against the possibility that an outlier perturbed sample will
dramatically influence the variance estimates. These results show that the proposed procedure still
performs reasonably well with smaller sample sizes. As expected, the variance is larger compared to
the large sample size setting but the bias is similar and the coverage is adequate.
5·2 Example
We illustrate our proposed procedures using data from the Diabetes Prevention Program (DPP), a
randomized clinical trial designed to investigate the efficacy of various treatments on the prevention
of type 2 diabetes in high-risk adults. At randomization, participants were randomly assigned to
one of four groups: metformin, troglitazone, lifestyle intervention or placebo. The troglitazone arm
of the study was discontinued due to medication toxicity. The primary endpoint was time to dia-
betes as defined by the protocol at the time of the visit: fasting glucose ≥ 140 mg/dL (for visits
through 6/23/1997, ≥ 126 mg/dL for visits on or after 6/24/2007) or 2-hour post challenge glucose
≥ 200 mg/dL. DPP results showed that both lifestyle intervention and metformin prevented or de-
layed development of type 2 diabetes in high risk adults (Diabetes Prevention Program Group, 1999;
Diabetes Prevention Program Group, 2002).
For this illustration, we focus on the comparison of the lifestyle intervention group (N=1024) vs.
placebo (N=1030) and we aim to examine the proportion of treatment effect explained by two potential
surrogate markers: change in log-transformed hemoglobin A1c (HBA1C) from baseline to t0 = 1 year
and change in fasting plasma glucose from baseline to t0. We define the treatment effect, ∆(t), as
the difference in diabetes prevalence at t = 3 years after randomization. Individuals who die before
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3 years are censored at the last time point where glucose was measured. The estimated probability
of not developing diabetes by t = 3 years was 0.86 in the lifestyle intervention group and 0.71 in the
placebo group; therefore the treatment effect ∆̂(t) = 0.86 − 0.71 = 0.15. Since we define surrogate
information at t0 as including diabetes incidence at t0, it is interesting to note that 3.7% and 11.5% of
participants in the lifestyle intervention group and placebo group were diagnosed with diabetes before
t0 = 1 year, respectively.
Results from estimating the proportion of treatment effect explained by each surrogate are shown in
Table 3. Using our proposed procedure, the estimated residual treatment effect, ∆̂S(t, t0), is 0.077 when
the surrogate information at 1 year post-baseline consists of information about the change in HBA1C
from baseline to 1 year and diabetes incidence up to 1 year and the proportion of treatment effect
explained by this surrogate information, RS(t, t0), is 48.2%. Examining change in fasting plasma
glucose, the estimated residual treatment effect is 0.046 when the surrogate information at 1 year
post-baseline consists of information about the change in fasting plasma glucose from baseline to
1 year and diabetes incidence up to 1 year and the proportion of treatment effect explained by this
surrogate information is 68.7%. To determine the incremental value of the information about change in
hemoglobin A1c and fasting plasma glucose, we examined the proportion of treatment effect explained
by diabetes incidence information only up to 1 year post-baseline which was estimated to be 47.8%.
Therefore, the incremental value of change in HBA1C was negligible, while the incremental value of
change in fasting plasma glucose was 21.0% (SE= 5.9%). Our application of the proposed procedures to
examine surrogate markers shows that fasting plasma glucose appears to capture more of the treatment
effect than hemoglobin A1c, particularly when considered in terms of incremental value when added
to diabetes incidence information at 1 year post-baseline.
To examine whether efficiency could be gained through augmentation, we also calculated our pro-
posed augmented estimates using the available baseline covariates: age group (less than 40, 40-44,45-
49,50-54,55-59,60-64,65 and older), body mass index category (km/m2 units, < 26, ≥ 26 to < 28,
21
≥ 28 to < 30, ≥ 30 to < 32, ≥ 32 to < 34, ≥ 34 to < 36, ≥ 36 to < 38, ≥ 38 to < 40, ≥ 40
to < 42, and ≥ 42), self-reported race/ethnicity (Caucasian, African American, Hispanic, other),
and gender. The resulting estimates for change in HBA1C were ∆̂(t)AUG = 0.15(SE = 0.019),
∆̂S(t, t0)
AUG = 0.078(SE = 0.017), and R̂S(t, t0)
AUG = 0.48(SE = 0.10). The resulting estimates for
change in fasting plasma glucose were ∆̂(t)AUG = 0.15(SE = 0.019), ∆̂S(t, t0)
AUG = 0.05(SE = 0.02),
and R̂S(t, t0)
AUG = 0.69(SE = 0.10). That is, in this particular example, the use of baseline covariates
through augmentation leads to little to no improvement in efficiency. Our application of the proposed
procedures to examine surrogate markers shows that fasting plasma glucose appears to capture more
of the treatment effect than HBA1C, particularly when considered in terms of incremental value when
added to diabetes incidence information at 1 year post-baseline.
6 Discussion
The identification and validation of surrogate markers is an important and challenging area of research.
Valid surrogate markers that could be used to replace the primary outcome or used in combination
with primary outcome information have the potential to lead to gains in efficiency in terms of design,
implementation, estimation and testing. In this paper we have proposed a novel model-free framework
for quantifying the proportion of treatment effect explained by surrogate information collected up to a
specified time in the survival setting and a robust nonparametric procedure for making inference. Our
proposed methods also have the advantage of allowing the surrogate marker S to be not observable at
time t0.
While we have defined the treatment effect quantity of interest as the difference in survival at
time t, our proposed definition and estimation procedure can be extended to other treatment effect
quantities such as the restricted mean survival time. Another option would be to define a treatment
effect quantity over time. When T is the time of a non-terminal primary outcome such as time until
diabetes diagnosis, there are two important considerations. First, competing risks must be accounted
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for in estimation since death could censor the observation of the primary outcome. Specifically, one
would censor an individual at the time of death and apply the procedures proposed above. Second,
it may be possible for the surrogate marker to still be observed after the primary outcome occurs is
individuals are still under observation in the study. However, depending on the setting, it may not
be appropriate to incorporate this surrogate marker information when estimating the proportion of
treatment effect because treatment decisions made after the primary outcome occurs may affect the
surrogate marker measurement in ways that would make the proportion of treatment effect estimation
uninterpretable. On the other hand, if the non-terminal primary outcome is an outcome that is not
easily observed and/or requires expensive, invasive or time-intensive testing to determine whether it
occurred, then use of a surrogate marker that may be measured after the event occurs may be of
interest.
The simulation study shows that the proposed inference procedure has satisfactory empirical perfor-
mance for moderate sample sizes. When the sample size becomes much smaller, these procedures which
are based on asymptotic normality approximations would still lead to reliable inference for ∆S(t, t0)
and ∆(t). However, the the asymptotical normality approximation of RS(t, t0), which involves the
ratio of ∆S(t, t0) and ∆(t), would likely be less reliable and the proposed inference method may not
be very accurate.
Lastly, a limitation of our proposed approach is the theoretical condition that the supports of S(A)
and S(B) are equivalent. In practice, the empirical supports may not completely overlap and some type
of transformation or extrapolation of the relevant nonparametric estimators may be needed. However,
when there is substantial non-overlap between two supports, caution is needed in interpreting the
results.
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Setting (i)
∆̂(t) ∆̂S(t, t0) R̂S(t, t0) ∆̂(t)
AUG ∆̂S(t, t0)
AUG R̂S(t, t0)
AUG
Bias -0.0002 0.0020 -0.0045 0.0000 0.0021 -0.0051
ESE 0.0254 0.0215 0.0962 0.0231 0.0213 0.0952
ASE 0.0249 0.0210 0.0988 0.0237 0.0208 0.0972
MSE 0.0006 0.0005 0.0093 0.0005 0.0005 0.0091
Coverage (normal) 0.951 0.945 0.959 0.958 0.947 0.955
Coverage (quantile) 0.945 0.943 0.942 0.953 0.944 0.941
Coverage (Fieller) – – 0.952 – – 0.953
Setting (ii)
∆̂(t) ∆̂S(t, t0) R̂S(t, t0) ∆̂(t)
AUG ∆̂S(t, t0)
AUG R̂S(t, t0)
AUG
Bias 0.0017 0.0017 -0.0041 0.0013 0.0017 -0.0043
ESE 0.0206 0.0140 0.0439 0.0176 0.0139 0.0430
ASE 0.0208 0.0141 0.0436 0.0178 0.0139 0.0429
MSE 0.0004 0.0002 0.0019 0.0003 0.0002 0.0019
Coverage (normal) 0.948 0.954 0.954 0.953 0.949 0.947
Coverage (quantile) 0.943 0.946 0.948 0.949 0.942 0.942
Coverage (Fieller) – – 0.953 – – 0.947
Table 1: Performance of the proposed estimates, the estimated treatment effect, ∆̂(t), the estimated residual treatment ef-
fect, ∆̂S(t, t0), the estimated proportion of treatment effect explained by surrogate information at t0, R̂S(t, t0), the estimated
augmented treatment effect, ∆̂(t)AUG, the estimated augmented residual treatment effect, ∆̂S(t, t0)
AUG, and the estimated aug-
mented proportion of treatment effect explained by surrogate information at t0, R̂S(t, t0)
AUG, in Settings (i) (top portion) and
(ii) (bottom portion) when nA = nB = 1000 in each group; the empirical standard error (ESE), average standard error (ASE),
mean squared error (MSE) and coverage of the 95% confidence intervals are shown for confidence intervals based on a normal
approximation, a quantile-based calculation, and Fieller’s method; the proposed perturbation-resampling procedure is used for
variance estimation
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Setting (i)
∆̂(t) ∆̂S(t, t0) R̂S(t, t0) ∆̂(t)
AUG ∆̂S(t, t0)
AUG R̂S(t, t0)
AUG
Bias -0.0009 0.0034 -0.0049 -0.0006 0.0036 -0.0062
ESE 0.0398 0.0329 0.1607 0.0362 0.0325 0.1552
ASE 0.0395 0.0326 0.1550 0.0375 0.0324 0.1517
MSE 0.0016 0.0011 0.0258 0.0013 0.0011 0.0241
Coverage (normal) 0.944 0.946 0.95 0.954 0.95 0.95
Coverage (quantile) 0.944 0.944 0.942 0.952 0.944 0.942
Coverage (Fieller) – – 0.944 – – 0.947
Setting (ii)
∆̂(t) ∆̂S(t, t0) R̂S(t, t0) ∆̂(t)
AUG ∆̂S(t, t0)
AUG R̂S(t, t0)
AUG
Bias 0.0025 0.001 -0.0006 0.0014 0.0011 -0.0012
ESE 0.0470 0.0315 0.0988 0.0405 0.0310 0.0965
ASE 0.0465 0.0313 0.1003 0.0400 0.0309 0.0973
MSE 0.0022 0.0010 0.0097 0.0016 0.001 0.0093
Coverage (normal) 0.949 0.949 0.960 0.943 0.953 0.959
Coverage (quantile) 0.947 0.951 0.953 0.939 0.952 0.947
Coverage (Fieller) – – 0.955 – – 0.955
Table 2: Performance of the proposed estimates, the estimated treatment effect, ∆̂(t), the estimated residual treatment ef-
fect, ∆̂S(t, t0), the estimated proportion of treatment effect explained by surrogate information at t0, R̂S(t, t0), the estimated
augmented treatment effect, ∆̂(t)AUG, the estimated augmented residual treatment effect, ∆̂S(t, t0)
AUG, and the estimated aug-
mented proportion of treatment effect explained by surrogate information at t0, R̂S(t, t0)
AUG, in Settings (i) (top portion) and
(ii) (bottom portion) when nA = nB = 400 in each group; the empirical standard error (ESE), average standard error (ASE),
mean squared error (MSE) and coverage of the 95% confidence intervals are shown for confidence intervals based on a normal
approximation, a quantile-based calculation, and Fieller’s method; the proposed perturbation-resampling procedure is used for
variance estimation
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Difference in HBA1C from baseline to t0
∆(t) ∆S(t, t0) RS(t, t0) ∆T (t, t0) RT (t, t0) IVS(t, t0)
Estimate 0.1483 0.0769 0.4815 0.0774 0.4779 0.0036
SE 0.0191 0.0167 0.1004 0.0162 0.0664 0.0984
95% CI (normal) (0.11,0.19) (0.04,0.11) (0.28,0.68) (0.05,0.11) (0.35,0.61) (-0.19,0.2)
95% CI (quantile) (0.11,0.18) (0.05,0.11) (0.25,0.65) (0.05,0.11) (0.35,0.62) (-0.23,0.17)
95% CI (Fieller) – – (0.27,0.68) – (0.36,0.62) –
Difference in fasting plasma glucose from baseline to t0
∆(t) ∆S(t, t0) RS(t, t0) ∆T (t, t0) RT (t, t0) IVS(t, t0)
Estimate1 0.1483 0.0464 0.6873 0.0774 0.4779 0.2094
SE1 0.0191 0.0181 0.098 0.0162 0.0664 0.0585
95% CI (normal)1 (0.11,0.19) (0.01,0.08) (0.5,0.88) (0.05,0.11) (0.35,0.61) (0.09,0.32)
95% CI (quantile)1 (0.11,0.18) (0.01,0.08) (0.52,0.9) (0.05,0.11) (0.35,0.62) (0.11,0.35)
95% CI (Fieller)1 – – (0.52,0.91) – (0.36,0.62) –
Table 3: Proposed estimates examining two potential surrogate markers in the Diabetes Prevention
Program: the estimated treatment effect, ∆̂(t), the estimated residual treatment effect using surro-
gate information at t0, ∆̂S(t, t0), the estimated proportion of treatment effect explained by surrogate
information at t0, R̂S(t, t0),the estimated residual treatment effect using survival information at t0
only, ∆̂T (t, t0), the estimated proportion of treatment effect explained by survival information only
at t0, R̂T (t, t0), the incremental value of the surrogate marker information, IVS(t, t0), with standard
error (SE) estimates obtained using the perturbation-resampling procedure and 95% confidence inter-
vals (CI) based on a normal approximation, a quantile-based calculation, and Fieller’s method where
t0 = 1 year and t = 3 years
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